BACKGROUND: Baseline plasma HIV RNA levels > 100 000 copies/ml have been associated with elevated mortality rates after the initiation of HAART. There is uncertainty regarding the optimal strategy for patients with high plasma HIV RNA but CD4 cell count > or = 200 cells/microl. OBJECTIVE: To evaluate the impact of baseline plasma HIV RNA on survival among patients with CD4 cell counts > or = 200 cells/microl. METHODS: Patients were stratified by plasma HIV RNA, CD4 cell count and adherence level. Mortality rates were evaluated using Kaplan-Meier methods and Cox regression. RESULTS: Among 1166 patients initiating HAART with a CD4 cell count > or = 200 cells/microl, a baseline HIV RNA > or = 100 000 copies/ml was statistically associated with elevated mortality among non-adherent patients (log-rank P = 0.032), but not for adherent patients (log-rank P = 0.690). In a multivariate Cox model comparing patients with a baseline CD4 cell count > or = 200 cells/microl and a baseline plasma HIV RNA < 100 000 copies/ml, the mortality rate was statistically similar among patients with a baseline CD4 cell count > or = 200 cells/microl and a baseline plasma HIV RNA > or = 100 000 copies/ml (relative hazard, 1.21; 95% confidence interval, 0.89-1.65; P = 0.232). CONCLUSION: HIV RNA > or = 100 000 copies/ml was only associated with mortality among HIV-infected patients initiating HAART with CD4 cell counts > or= 200 cells/microl if the patients were non-adherent.
BACKGROUND: Baseline plasma HIV RNA levels > 100 000 copies/ml have been associated with elevated mortality rates after the initiation of HAART. There is uncertainty regarding the optimal strategy for patients with high plasma HIV RNA but CD4 cell count > or = 200 cells/microl. OBJECTIVE: To evaluate the impact of baseline plasma HIV RNA on survival among patients with CD4 cell counts > or = 200 cells/microl. METHODS:Patients were stratified by plasma HIV RNA, CD4 cell count and adherence level. Mortality rates were evaluated using Kaplan-Meier methods and Cox regression. RESULTS: Among 1166 patients initiating HAART with a CD4 cell count > or = 200 cells/microl, a baseline HIV RNA > or = 100 000 copies/ml was statistically associated with elevated mortality among non-adherent patients (log-rank P = 0.032), but not for adherent patients (log-rank P = 0.690). In a multivariate Cox model comparing patients with a baseline CD4 cell count > or = 200 cells/microl and a baseline plasma HIV RNA < 100 000 copies/ml, the mortality rate was statistically similar among patients with a baseline CD4 cell count > or = 200 cells/microl and a baseline plasma HIV RNA > or = 100 000 copies/ml (relative hazard, 1.21; 95% confidence interval, 0.89-1.65; P = 0.232). CONCLUSION: HIV RNA > or = 100 000 copies/ml was only associated with mortality among HIV-infectedpatients initiating HAART with CD4 cell counts > or= 200 cells/microl if the patients were non-adherent.
Authors: Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg Journal: Curr HIV/AIDS Rep Date: 2011-12 Impact factor: 5.071
Authors: Peng Wu; Brent A Johnson; Jean B Nachega; Baohua Wu; Claudia E Ordonez; Anna Q Hare; Rachel Kearns; Richard Murphy; Henry Sunpath; Vincent C Marconi Journal: Curr HIV Res Date: 2014 Impact factor: 1.581
Authors: James G Carlucci; Aniset Kamanga; Robb Sheneberger; Bryan E Shepherd; Cathy A Jenkins; John Spurrier; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Christopher G Au-Yeung; Aranka Anema; Keith Chan; Benita Yip; Julio S G Montaner; Robert S Hogg Journal: BMC Public Health Date: 2010-10-25 Impact factor: 3.295
Authors: Jean B Nachega; Michael Hislop; Hoang Nguyen; David W Dowdy; Richard E Chaisson; Leon Regensberg; Mark Cotton; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731
Authors: A Antinori; A Ammassari; C Torti; P Marconi; M Andreoni; G Angarano; S Bonora; A Castagna; R Cauda; M Clerici; A d'Arminio Monforte; A De Luca; G Di Perri; M Galli; E Girardi; A Gori; A Lazzarin; S Lo Caputo; F Mazzotta; F Montella; C Mussini; C F Perno; M Puoti; G Rizzardini; S Rusconi; V Vullo; G Carosi Journal: Infection Date: 2009-05-28 Impact factor: 3.553
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Joel E Gallant; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: AIDS Date: 2008-10-18 Impact factor: 4.177